Back to top
more

Vericel (VCEL)

(Delayed Data from NSDQ)

$36.82 USD

36.82
488,239

-0.76 (-2.02%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $36.82 0.00 (0.00%) 7:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Will Vericel Corporation (VCEL) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Vericel Corporation (VCEL) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Vericel Corporation (VCEL) closed at $42.92, marking a -0.26% move from the previous day.

Zacks Equity Research

Global Blood (GBT) Q4 Earnings Miss, Revenues Beat Estimates

by Zacks Equity Research

Global Blood (GBT) reports a wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates.

Zacks Equity Research

Company News for Feb 25, 2021

by Zacks Equity Research

Companies In The News Are: VCEL, LNG, HZNP, PRAH

Zacks Equity Research

ACADIA (ACAD) Beats on Q4 Earnings, Misses on Revenues

by Zacks Equity Research

ACADIA's (ACAD) loss narrows in the fourth quarter of 2020 while it misses estimates for revenues. Nuplazid drives year-over-year revenues.

Zacks Equity Research

Vericel Corporation (VCEL) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Vericel Corporation (VCEL) delivered earnings and revenue surprises of 19.05% and 0.40%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Blueprint Medicines (BPMC) Q4 Earnings Beat, Revenues In Line

by Zacks Equity Research

Blueprint Medicines' (BPMC) earnings beat estimates in the fourth quarter of 2020 while revenues meet the same. Shares up.

Zacks Equity Research

Vericel Corporation (VCEL) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Vericel Corporation (VCEL) closed at $51.15, marking a -0.04% move from the previous day.

Zacks Equity Research

Vericel Corporation (VCEL) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Has Vericel (VCEL) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (VCEL) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Fall Y/Y

by Zacks Equity Research

CRISPR Therapeutics (CRSP) misses estimates for both earnings and revenues in the fourth quarter of 2020. Focus on pipeline development.

Zacks Equity Research

Seagen (SGEN) Gets European Commission Nod for Breast Cancer Drug

by Zacks Equity Research

The European Commission approves Seagen's (SGEN) Tukysa in combination with Herceptin and Xeloda to treat adults with HER2-positive locally advanced or metastatic breast cancer.

Zacks Equity Research

Is a Beat in the Cards for CVS Health (CVS) in Q4 Earnings?

by Zacks Equity Research

Through November and December, the resurgence of new COVID-19 cases might have resulted in more COVID-19 tests conducts by CVS Health (CVS).

Zacks Equity Research

Higher Testing Volume to Aid LabCorp's (LH) Q4 Earnings

by Zacks Equity Research

LabCorp's (LH) fourth-quarter base-business performance is expected to have registered slower recovery rate compared to the third quarter.

Zacks Equity Research

Vericel Corporation (VCEL) Moves to Strong Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Vericel Corporation (VCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Vericel, Intuit, Mosaic, Ally Financial and D.R. Horton highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Vericel, Intuit, Mosaic, Ally Financial and D.R. Horton highlighted as Zacks Bull and Bear of the Day

Kevin Cook headshot

Bull of the Day: Vericel (VCEL)

by Kevin Cook

Restoring cartilage in sports medicine and rebuilding skin after severe burns gave this small-cap big upside

Zacks Equity Research

Zacks Market Edge Highlights: Vericel, Tesla, Chewy, Alibaba and Facebook

by Zacks Equity Research

Zacks Market Edge Highlights: Vericel, Tesla, Chewy, Alibaba and Facebook

Tracey Ryniec headshot

Should You Sell Your Big Winner Stocks?

by Tracey Ryniec

One of the most difficult parts of investing is knowing when to sell your stocks. After a red hot 2020, what should you do?

Tracey Ryniec headshot

Stock Investors: What's the Next Hot Industry?

by Tracey Ryniec

Technology won't always be on top. There's a bunch of budding industries that could prove to be winners over the next 5 years.

Zacks Equity Research

Vericel Corp, Nikola Corp, Lowe's, Dollar General and Best Buy highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Vericel Corp, Nikola Corp, Lowe's, Dollar General and Best Buy highlighted as Zacks Bull and Bear of the Day

Kevin Cook headshot

Bull of the Day: Vericel (VCEL)

by Kevin Cook

Restoring cartilage in sports medicine and rebuilding skin after severe burns gives this small-cap big upside

Zacks Equity Research

Vericel Corp (VCEL) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Vericel Corp (VCEL) has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Equity Research

Alkermes (ALKS) Beats on Q3 Earnings & Sales, Lifts Guidance

by Zacks Equity Research

Alkermes (ALKS) beats earnings and sales estimates in the third quarter of 2020. The company also raises 2020 guidance.

Zacks Equity Research

Alexion (ALXN) Beats on Q3 Earnings & Sales, Ups '20 Guidance

by Zacks Equity Research

Alexion (ALXN) beats earnings and sales estimates in the third quarter of 2020.